Metabolic changes in patients with prostate cancer with androgen deprivation therapy

Prostate cancer is the most common type of cancer among men. Androgen deprivation therapy (ADT) is the most effective treatment for this disease. The cornerstone of prostate cancer treatment is the inhibition of testosterone production, which interrupts testosterone-induced growth of the prostate tu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maxim N. Peshkov, Galina P. Peshkova, Igor V. Reshetov
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2020
Materias:	prostate cancer metabolic syndrome diabetes mellitus insulin resistance body vass index obesity dyslipidemia Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/3884afa15db648edbc942fa54a507248
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3884afa15db648edbc942fa54a507248
record_format	dspace
spelling	oai:doaj.org-article:3884afa15db648edbc942fa54a5072482021-11-14T09:00:23ZMetabolic changes in patients with prostate cancer with androgen deprivation therapy2072-03512072-037810.14341/DM10343https://doaj.org/article/3884afa15db648edbc942fa54a5072482020-06-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/10343https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Prostate cancer is the most common type of cancer among men. Androgen deprivation therapy (ADT) is the most effective treatment for this disease. The cornerstone of prostate cancer treatment is the inhibition of testosterone production, which interrupts testosterone-induced growth of the prostate tumour. A sharp decrease in testosterone, however, has several undesirable effects on the metabolic profile and bone metabolism and can also lead to fatigue, loss of libido, gynecomastia and anaemia, provoke vasomotor hyperaemia and generally affect the quality of life. To increase the good (long-term) survival of patients with prostate cancer, studying the side effects associated with treatment is important, and therefore, in every clinical situation, the benefits of ADT must be compared with the side effects associated with the treatment. This article focuses on the described metabolic complications of ADT, including obesity, diabetes, lipid changes, metabolic syndrome and cardiovascular diseases. It also contains practical recommendations for managing the side effects and complications based on the available guidelines issued by the medical professional community.Maxim N. PeshkovGalina P. PeshkovaIgor V. ReshetovEndocrinology Research Centrearticleprostate cancermetabolic syndromediabetes mellitusinsulin resistancebody vass indexobesitydyslipidemiaNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 23, Iss 2, Pp 192-200 (2020)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	prostate cancer metabolic syndrome diabetes mellitus insulin resistance body vass index obesity dyslipidemia Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	prostate cancer metabolic syndrome diabetes mellitus insulin resistance body vass index obesity dyslipidemia Nutritional diseases. Deficiency diseases RC620-627 Maxim N. Peshkov Galina P. Peshkova Igor V. Reshetov Metabolic changes in patients with prostate cancer with androgen deprivation therapy
description	Prostate cancer is the most common type of cancer among men. Androgen deprivation therapy (ADT) is the most effective treatment for this disease. The cornerstone of prostate cancer treatment is the inhibition of testosterone production, which interrupts testosterone-induced growth of the prostate tumour. A sharp decrease in testosterone, however, has several undesirable effects on the metabolic profile and bone metabolism and can also lead to fatigue, loss of libido, gynecomastia and anaemia, provoke vasomotor hyperaemia and generally affect the quality of life. To increase the good (long-term) survival of patients with prostate cancer, studying the side effects associated with treatment is important, and therefore, in every clinical situation, the benefits of ADT must be compared with the side effects associated with the treatment. This article focuses on the described metabolic complications of ADT, including obesity, diabetes, lipid changes, metabolic syndrome and cardiovascular diseases. It also contains practical recommendations for managing the side effects and complications based on the available guidelines issued by the medical professional community.
format	article
author	Maxim N. Peshkov Galina P. Peshkova Igor V. Reshetov
author_facet	Maxim N. Peshkov Galina P. Peshkova Igor V. Reshetov
author_sort	Maxim N. Peshkov
title	Metabolic changes in patients with prostate cancer with androgen deprivation therapy
title_short	Metabolic changes in patients with prostate cancer with androgen deprivation therapy
title_full	Metabolic changes in patients with prostate cancer with androgen deprivation therapy
title_fullStr	Metabolic changes in patients with prostate cancer with androgen deprivation therapy
title_full_unstemmed	Metabolic changes in patients with prostate cancer with androgen deprivation therapy
title_sort	metabolic changes in patients with prostate cancer with androgen deprivation therapy
publisher	Endocrinology Research Centre
publishDate	2020
url	https://doaj.org/article/3884afa15db648edbc942fa54a507248
work_keys_str_mv	AT maximnpeshkov metabolicchangesinpatientswithprostatecancerwithandrogendeprivationtherapy AT galinappeshkova metabolicchangesinpatientswithprostatecancerwithandrogendeprivationtherapy AT igorvreshetov metabolicchangesinpatientswithprostatecancerwithandrogendeprivationtherapy
_version_	1718429458953666560

Metabolic changes in patients with prostate cancer with androgen deprivation therapy

Ejemplares similares